Cognitive Assessment Tools for Huntington's Disease.

Subjects will be recruited from the OSU Wexner Medical Center Huntington Society of America Center of Excellence Clinic. Subjects will be scheduled for a one-time visit to complete the study. The entire visit will take approximately 1-1.5 hours. Vital signs (weight, blood pressure, temperature, respiratory rate and pulse) will be conducted. The subject's medical records will be reviewed to obtain their demographics, current medications, medical/surgical/ HD family history, and HD diagnosis details. If any adverse events occur during the research visit they will be documented. Participants will complete cognitive, functional and motor assessments.

Inclusion criteria

• Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
• Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
• A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
• Vision and hearing sufficient for compliance with tests.
• On a stable dose of medications for 30 days prior to the time of signing the informed consent form.

Exclusion criteria

• Age of symptom onset less than 19 years old or greater than 60 years old.
• Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant.
• Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).
• Subjects who are pregnant or breast feeding
• Subjects with a history of a learning disability.
• Subjects who are unable to provide consent.